HANC Newsletter  |  January 2022

Land, Labor, and Justice Acknowledgements

We acknowledge the land we occupy today as the traditional home of the Duwamish, Tulalip, Muckleshoot, and Suquamish tribal nations, the original caretakers of this land who are still here. Without them we would not have access to this working, teaching, and learning environment. We commit to conducting ourselves with dignity and treating this land and all the life it sustains with respect. We ask you to join us in this commitment, wherever you may reside. We also acknowledge exploited labor and ongoing struggle​s for justice on this land. We reflect on the ancestors of our various peoples, nations, tribes, and families; ancestors whose struggles, pain, power, privilege, and strivings we hold in our very bodies.

HANC offices are located at Fred Hutch campus in Seattle, WA.

CFAR CDEIPI Award – Evidence2Practice

The Duke Center for AIDS Research (CFAR) has received a supplement of $150,000 as part of the CFAR Diversity, Equity, and Inclusion Pipeline Initiative (CDEIPI). Duke CFAR’s submission to the program is entitled: “Evidence2Practice (E2P): Leveraging implementation science to recruit HBCU/MSI students into careers in HIV research”

Evidence2Practice (E2P) is an intensive on-campus workshop-based initiative to increase student interest in careers in HIV science by providing an experience-based introduction to implementation science. E2P developed out of a 4-year partnership between Dr. Nwora Lance Okeke, MD, MPH (Assistant Professor, Division of Infectious Diseases), Dr. Kenric B. Ware, PharmD (Associate Professor of Pharmacy, South University) and Russell Campbell, MA (Deputy Director, HANC). Through this collaboration, Dr. Okeke, Dr. Ware and Mr. Campbell created the Bringing PrEP to Campus (BPC) program in 2018 which created campus-specific strategies for HIV prevention at Historically Black Colleges and Universities (HBCUs). BPC was anchored by the Legacy Project's Be the Generation curriculum.

Evidence2Practice is a reconfiguration of the BPC program, evolved to better respond to CDEIPI’s call to increase HBCU students’ interest in HIV science careers. E2P will be led by Dr. Okeke and Dr. Amy Corneli (Associate Professor of Population Health) in partnership with Dr. Ware and Mr. Campbell. E2P’s 3-day interactive workshops will be held at six HBCUs in South Carolina, a priority jurisdiction of the Department of Health and Human Services Ending the HIV Epidemic, over Spring Semester 2021-22 and Fall Semester 2022-23. 
 

H=H Episode 3: A Conversation with Dr. Carl Dieffenbach

This first episode of 2022 comes with an exclusive interview with Dr. Carl Dieffenbach, the Director of the Division of AIDS of the National Institutes of Health. Together we talk about:
  • What is the Division of AIDS?
  • Where is DAIDS located within the National Institutes of Health?
  • What are the prevention and therapeutic agendas of the HIV/AIDS research networks?
  • How is the COVID-19 pandemic impacting HIV research?
  • What has been the role of the community in COVID-19 research? 
Listen online at RedCircle or Spotify.
The ACTG congratulates the 2021 Tuberculosis Transformative Science Group Special Contributions Award recipients: Nishi Suryavanshi, PhD, from the Byramjee Jeejeebhoy Medical College CRS and Yvetot Joseph, MD, from the GHESKIO Institute of Infectious Diseases and Reproductive Health CRS. This award was developed to recognize the many site team members and investigators that go above and beyond to help implement TB studies at their sites. The TB TSG recognized there are no current ACTG awards for these individuals and believe it is important to recognize their efforts. Congratulations, Drs. Suryavanshi and Joseph!!

Last month, the ACTG announced the initiation of A5355, a clinical trial studying a new CMV vaccine in adults with both HIV and CVM. Congratulations to the study team! Read more HERE.
 
 
Data from HPTN studies HPTN 083 and HPTN 084 helped provide important information for the  December 20, 2021 decision by the U.S. Food and Drug Administration (FDA) to approve ViiV Healthcare’s long-acting cabotegravir (CAB-LA) injections for the prevention of HIV. Sponsored and co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), these studies showed that CAB-LA injected once every eight weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention among cisgender men and transgender women who have sex with men (HPTN 083) and cisgender women (HPTN 084). Both studies also demonstrated that CAB-LA was well-tolerated, offering a new and important pre-exposure prophylaxis (PrEP) option for individuals at risk for HIV infection.  ViiV Healthcare will market CAB-LA for PrEP under the brand name Apretude. 

 
HVTN Community Compass
We are inspired by your continued support of HVTN Community Compass! Each edition is a collection of stories conveying the passion and unwavering commitment of our pursuit for a safe and globally effective preventive HIV vaccine. We hope this edition will be another informative read to grow your knowledge and understanding of the HIV prevention field and to celebrate how you are making an impact!

Community Compass is available in English, Spanish, Portuguese, and French and these translations will soon be available online here. Please share this publication with your networks, colleagues, friends and family members. If you are at a clinical trial site/or clinical trial unit, please be sure to share copies of the magazine with your CABs and local communities after you receive them.

In this edition we share and celebrate the journeys of previous cohort members of the HVTN Research and Mentorship Program (RAMP) Scholar Program for African American/Black and Latinx Medical Students, and share community engagement activities from some of our research sites, our Faith Initiative efforts, an award presented to our very own Dr. Larry Corey and Dr. Kathleen Neuzil, CoVPN acknowledgements, and important messages and updates from one of our CAB members and one of our community partners. 
 
Despite the ongoing challenges of the COVID-19 pandemic, the IMPAACT Network met several key milestones and realized many successful achievements in 2021. We are so thankful for the ongoing dedication and resilience of our site staff, study participants, and the support of their communities during these ongoing challenging times.

The HANC-facilitated COVID-19 CAB Coalition (CCC) formed in September 2020 to share information, share resources, and advocate on behalf of COVID-19 research efforts. Members represent the COVID-19 Prevention Network (CoVPN) Community Engagement Working Group, the ACTG's ACTIV-2 CAB, AVAC's COVID Advocates Advisory Board, the CFAR National CAB Coalition, the COVID-19 CAB at Stony Brook, DAIDS, and Community Partners.

Updates from the CCC are shared below:
 
COVID-19 CAB Coalition Update
On the last COVID-19 CAB Coalition (CCC) call, the group discussed the need for materials that explain how science is an evolutionary process and that knowledge changes overtime. HANC staff are reviewing the HANC basic scientific literacy training to see if it could be included in the materials. HANC has discussed writing several short scripts based on the basic scientific literacy training to create brief videos that can be shared via social media.
 
"Taking Cues: Lessons from the HIV Pandemic to Guide COVID-19 Responses" Video
On August 2, 2021, the HANC-facilitated Behavioral Science Consultative Group published the paper, "Individual health behaviours to combat the COVID-19 pandemic: lessons from HIV socio-behavioural science" in the Journal of the International AIDS Society. Shortly after publication, the BSCG sought to create a short video highlighting key components of the paper in effort to reach populations that do not read scientific articles and/or journals. In late December 2021, the final version of the video, "Taking Cues: Lessons from the HIV Pandemic to Guide COVID-19 Responses" was posted on YouTube. Please share the YouTube link with your networks.
Upcoming COVID-19 webinar of interest
AVAC's COVID Advocates Advisory Board (CAAB) is hosting a webinar, "Understanding - And Improving - COVID-19 Vaccine Uptake" in collaboration with the Coalition to Accelerate and Support Prevention Research (CASPR) on January 10, 2022 at 10am ET for a close look at how global health leaders are tackling public resistance to COVID-19 vaccines, and lessons from the HIV field. Register for the webinar here. For more information on the CAAB, click here.
 
Update on the Novavax COVID-19 vaccine
On December, 31, 2021, Novavax announced that they submitted the final data packages to the U.S. FDA as a prerequisite to EMA application request for COVID-19 vaccine. Read more here.
Behavioral and Social Sciences

Greg Davis, HANC Project Manager
The Youth Prevention Research Working Group (YPRWG) is forming an ad-hoc group to create a recommendations sheet based on the results from the YPRWG site survey and report. Once the recommendations are completed, the report will be available on the HANC website.

The Behavioral Science Consultative Group (BSCG) is tentatively scheduled to meet in-person on March 11, 2022, in Seattle, WA. The BSCG is currentlly developing the agenda for the F2F meeting. The BSCG is happy to annouce that the accompanying video to the paper, "Individual health behaviours to combat the COVID-19 pandemic: lessons from HIV socio-behavioural science" has been posted on YouTube
 
Community Partners

Russell Campbell, HANC Deputy Director
For those interested in learning more about becoming a Community Advisory Board or Community Working Group member, the Division of AIDS Directory for HIV Research Community Advisory Boards & Community Working Groups Directory DAIDS CAB & CWG Directory is a great resource.
 
Cross-Network Coordination

Milan Vu, HANC Project Manager
Representatives from the DAIDS Office of Clinical Site Oversight (OCSO) joined the Cross-Network Site Coordinators Working Group (SCWG) meeting this month to discuss site needs related to remote regulatory inspection, the co-enrollment prevention requirements, and other site concerns.

New DAIDS Memo: Expansion of Medidata RSR to facilitate rSDV
A memo was released on December 20, 2021 providing information on the status, plans, and expectations for remote monitoring of studies configured in Medidata Remote Source Review (RSR). The memo also includes guidance on use of Medidata RSR for all DAIDS sponsored studies. Find the memo on the HANC website.

December issue of DAIDS MOB Newsletter
The December edition of the DAIDS Monitoring Operations Branch (MOB) report was released and discusses the expansion of Medidata RSR and tips for remote regulatory assessments.
 
Laboratory Coordination

Tyler Brown, HANC Project Manager
In December the Lab Technologists Committee (LTC) welcomed two new members, Patrick Mehta (University of Pittsburgh CRS) and Terence Mohammed (Gaborone CRS), who were elected to the committee and will serve as members December 1, 2021 - November 30, 2023. Welcome Patrick and Terence!

The HANC-LTC SOP Working Group held two conference calls in December to continue developing a new standard wording guide for ACTG and IMPAACT protocol Lab Processing Charts (LPCs) – the new guide is expected to be published by March 2022.

In December HANC and the CPQA Program launched the Qualitative Assay Working Group, a new working group charged with developing a new set of guidelines for qualitative ARV pharmacology assays. The new guidelines are expected to be published in the first half of 2022.

The CPQA Cross-Network Clinical Pharmacology Forum (CNCPL Forum) held a meeting in December on which the group discussed current and upcoming CPQA proficiency testing rounds, future network study compounds, and updates on the CPQA AVR/SOP Review Program.

Reminder: In November DAIDS Clinical Laboratory Oversight Team (DCLOT) issued a memo that clarifies Good Clinical Laboratory Practice (GCLP) training requirements for non-lab personnel (such as nurses) who perform specimen processing and/or rapid testing in the clinic or clinical laboratory. Follow this link to access the memo online.
 
The Legacy Project

Brian Minalga and Pedro Goicochea, HANC Community Engagement Officers
Jan 3: The Legacy Project launched Episode 3 of the podcast “H=H, the H is for Human,” with an exclusive interview with Dr. Carl Dieffenbach, Director for the Division of AIDS.  Listen to Episode 3 here.  

Jan 21: Abstract deadline for submission to the International Workshop on HIV & Women. The Women’s HIV Research Collaborative has submitted two abstracts: one on PrEP for cisgender women of color, and another on the gender-specific findings from the 2021 Representative Studies Rubric analysis.

Jan 27: Abstract deadline for submission to AIDS 2022. The Legacy Project’s various working groups plan to submit abstracts on the topics of HIV Prevention Research trainings, the Representative Studies Rubric, HIV prevention for women, Addictophobia in HIV/AIDS Clinical Research and HBCU Engagement.

Jan 31: The Legacy Project will be hosting the 3rd webinar in the Addictophobia in HIV/AIDS Clinical Research series. This webinar will feature a moderated panel of individuals with lived experience who will share how addictophobia and stigma impact accessing general health care services like needle exchange programs, substance use treatment, HIV care and participation in research. The focus of the panel will be to discuss some of these issues and share what’s needed to change these systems. Register for the webinar here. For reference, here are the links to our first two webinars: Addictophobia Part 1 and Addictophobia Part 2.
 

Webinars

January 31, 2022 at 9-10:30am PST | 12-1:30pm EST | 7-8:30pm SAST
The Legacy Project at the Office of HIV/AIDS Network Coordination invites you to participate in the 3rd webinar of the Addictophobia in HIV/AIDS Clinical Research series. During this webinar, a moderated panel of individuals with lived experience will share how addictophobia and stigma impact accessing general health care services like needle exchange programs, substance use treatment, HIV care and participation in research. The focus of this moderated panel will be to discuss some of these issues and share what’s needed to change these systems. Please click here to register
  • Implicit Association Survey for PWID: What are your automatic reactions when you think about people who use drugs? The following survey will provide an insight into your thoughts about substance use disorder that are difficult to consciously control. As part of this webinar series, we invite you to complete a brief questionnaire and a validated Implicit Association Test in which you will sort words and pictures into categories as quickly as possible. You should be able to complete the tasks in less than 10 minutes total.  Please click here to complete the survey.
 

Training

The updated Spanish and Portuguese translated versions of the below courses are now available on the DAIDS Learning portal. These trainings are comprised of 14 modules that cover various processes that need to be followed by CRS staff, who are participating in DAIDS-supported and/or sponsored clinical trials, to provide an introduction to GCLP and their relationship to clinical research. You can check which courses are required for you to complete here.
 

Job Opportunities

Applications due January 17, 2022
The Summer HIV/AIDS Research Program (SHARP) is excited to welcome a new cohort of six undergraduate/immediate post-graduate scholars from underrepresented minority backgrounds for a paid, mentored HIV research internship this summer 2022. Applications are now open and accepted until January 17, 2022. See the SHARP flyer for more information and apply on the SHARP website.

SHARP is funded by the National Institute on Drug Abuse (NIDA) and co-hosted by Bridge HIV and local research partners at the San Francisco Department of Public Health (SFDPH) and University of California, San Francisco (UCSF).
HPTN 096 is a community-randomized study that will evaluate an integrated strategy comprised of four interventions. These interventions aim to increase HIV testing, the use of pre-exposure prophylaxis (PrEP) and viral suppression rates among Black men who have sex with men (MSM) (> 15 years old) living in the southern United States (US).

The HPTN 096 study team is establishing a HIV-status neutral peer to peer support program and is seeking a licensed supervisor, who is familiar with the cultural factors and health disparities that Black MSM face in the South. This position will be responsible for providing training, supervision, coaching, mentoring and oversight to peer support workers, who, in turn, will provide motivational, emotional, and informational support to Black MSM and help them connect with Black MSM-centered health and support services. View the full job description here. To apply, forward a cover letter and resume/CV to 096_PS_Queries@hptn.org with the subject line Clinical Supervisor Position.
 

Conferences & Meetings

February 12-16, 2022
May 4-6, 2022
HVTN Full Group Meeting (Washington, DC USA)
June 4-8, 2022
HPTN Annual Meeting (Hybrid: Washington, DC USA)
June 13-17, 2022
Annual ACTG Network Meeting (Washington, DC USA)
June 28-July 1, 2022
IMPAACT Annual Meeting (Hybrid: Washington, DC USA)